Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer

IMPORTANCE: Combining conventional chemotherapy with targeted therapy has been proposed to improve the pathologic complete response (pCR) rate in patients with inflammatory breast cancer (IBC). Epidermal growth factor receptor (EGFR) expression is an independent predictor of low overall survival in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Matsuda, Naoko, Wang, Xiaoping, Lim, Bora, Krishnamurthy, Savitri, Alvarez, Ricardo H., Willey, Jie S., Parker, Charla A., Song, Juhee, Shen, Yu, Hu, Jianhua, Wu, Wenhui, Li, Nan, Babiera, Gildy V., Murray, James L., Arun, Banu K., Brewster, Abenaa M., Reuben, James M., Stauder, Michael C., Barnett, Chad M., Woodward, Wendy A., Le-Petross, H. T. Carisa, Lucci, Anthony, DeSnyder, Sarah M., Tripathy, Debu, Valero, Vicente, Ueno, Naoto T.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2018
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143003/
https://ncbi.nlm.nih.gov/pubmed/29879283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.1436
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars